Key Documents
Ash A. Alizadeh, MD/PhD
Academic Appointments
- Instructor, Medicine - Oncology
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr MC 5820 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 724-5203
- Academic Offices
Personal Information EmailAdministrative Contact Tel Work 650-498-6000Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Lymphoproliferative Disorders
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Lymphoma
- Oncology
Honors and Awards
- Clinical Investigator Program: Fellow Award, Stanford University Medical Center (2004-2010)
- Franklin G. Ebaugh, Jr. Award for Outstanding Research, Dept of Medicine, Stanford (2004-2005)
- Sandler Fellow Award, UCSF (2003-2004)
- Medical Scientist Training Program Award, NIH (1996-2003)
- Research Scholar Award for Outstanding Research, HHMI (1998)
Professional Education
| Fellowship: | Stanford University School of Medicine, CA USA (2009) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2008) |
| Residency: | Stanford University school of Medicine, CA USA (2006) |
| Internship: | Stanford University school of Medicine, CA USA (2005) |
| Fellowship: | UCSF, CA USA (2004) |
Graduate & Fellowship Program Affiliations
Web Site Links
Scientific Focus
Current Research Interests
My research is focused on attaining a better understanding of the initiation, maintenance, and progression of lymphoid tumors, and their response to immunochemotherapy toward improving current treatment strategies.
In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models. I hope to apply this knowledge towards the design of clinical trials in the treatment of patients with lymphoma, leukemia, and myeloma.
Publications
- A pluripotency signature predicts histological transformation and influences survival in follicular lymphoma patients Blood. 2009
- Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med. 2009; (26): 2794-5
- CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; (2): 286-99
- SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res. 2003; (1): 219-23
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; (6769): 503-11